Investors

 

Questions and Answers

2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders. With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available.
Additional questions/comments should be mailed to info@2curex.com.


  • This is true for colon cancer on average for the different stages of the disease. For late stage (IV), where the disease has spread to distant organs, most often the liver, the response is significantly lower.

  • As mentioned above it is not the accuracy of the IndiTreat® test that is 58%, it is its ability, in the tested patient population, to identify an effective treatment. The reasons for it not being higher is that some patients will show resistance or low sensitivity towards all the treatments tested. It is likely that the percentage will go up when we include other types of cancer drugs in the test panel.

  • None of the mentioned competitors are running clinical trials in colon cancer.

  • We will release information from the clinical trial before its finalization – we expect to inform the market about the status of the trial in the summer of 2018.

  • Yes, the first patients were enrolled end of October 2017. In February 2018 we had successfully enrolled the first 10 patients.

  • We were very successful with our EU application and received EURO 3 Mill in funding. The funds will be used to support our clinical studies and commercialization of the IndiTreat® test. The funds will directly support the business plan of 2cureX.

  • The IndiTreat technology is easy to scale, and one person can run a large number of test in parallel. Setting up the test facility is relatively easy done – it requires access to the 2cureX know how and patent rights; but is not demanding staff wise. With regard to setup of test-sites we have strategically decided that we want to have presence in all countries where we operate. This will have a very positive effect on the general uptake of the test in the individual countries.

  • Thank you for pointing this issue to our attention. We have been in contact with Nordnet and our news distributor (Cision). It turns out that there has been an error in the distribution algorithm. This is very unfortunate. The error is now corrected. So, in the future you will see the important press releases from 2cureX on Nordnet’s web-site.

Contact information

Laboratory: 2cureX, Building 8, 2. Tværvej, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint